Sign in
CompletedNo phase

Comparison of the Pain and Functional Improvement of Combined Extracorporeal Shockwave Therapy With or Without Intra-articular Hyaluronic Acid and Platelet-rich Plasma Injection on Advanced Osteoarthritis of the Knees.

Key facts

Who runs it
Chang Gung Memorial Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
48 people enrolled
Started
4 Aug 2023
Ended
27 Jun 2025
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Extracorporeal Shock Wave Therapy
  • Normal Saline
  • Hyaluronic Acid (HA)
  • Platelet-Rich Plasma
Record updated
15 September 2026

Who can take part

Age
20 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Patients aged 20 years and older with phase II, III, or IV osteoarthritis of the knee. The phase of osteoarthritis of the knee is defined according to the Kellgren-Lawrence classification; phase II: Only slight narrowing of the joint cavity, with visible bone spurs; phase III: Numerous bone spurs, significant narrowing of the joint cavity, and subchondral cysts visible in the subchondral bone; phase IV: Larger and more prominent bone spurs, severe narrowing of the joint cavity, sclerosis of the subchondral bone, and even joint deformities

Who cannot take part

  • Patients with arrhythmia or those with pacemakers
  • Individuals with coagulation disorders
  • Patients with chronic renal failure (glomerular filtration rate < 60)
  • Patients with known allergies to hyaluronic acid, or those with infections or skin diseases
  • Pregnant or breastfeeding women
  • Patients with tumors

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This was a single group, double-blind, randomized clinical trial that enrolled 48 patients with Kellgren-Lawrence grade II to IV osteoarthritis of the knee. Patients were randomly assigned to three groups: Saline + ESWT (S+E group), High Platelet-Rich Plasma (PRP + ESWT (P+E group), and Hyaluronic Acid + ESWT (HA + ESWT (H+E group). All patients were followed for one year. Assessments included the Visual Analogue Scale (VAS), serum enzyme-linked immunosorbent assay (ELISA), knee X-ray and ultrasound examinations, and functional scores (WOMAC, KOOS, and IKDC).

The 3 groups in the trial

  • ESWT+normal salinePlacebo, for comparison

    Each group received ESWT treatment and an injection of Saline as a placebo to prevent participants from knowing they were in the control group.

    Treatment: Extracorporeal Shock Wave Therapy and Normal Saline

  • ESWT+Hyaluronic Acid(HA)Treatment being tested

    This group of patients will receive ESWT and HA injections.

    Treatment: Extracorporeal Shock Wave Therapy and Hyaluronic Acid (HA)

  • ESWT+Platelet-Rich Plasma(PRP)Treatment being tested

    This group of patients will receive ESWT and PRP injections.

    Treatment: Extracorporeal Shock Wave Therapy and Platelet-Rich Plasma

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
15 September 2026